APGE - Company ID 0001974640
The table below shows Apogee Therapeutics, Inc.'s balance sheet line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash & equivalents | $131.55M | $141.79M | $118.32M |
| Short-term investments | $598.64M | $378.86M | $277.14M |
| Receivables | - | - | - |
| Inventory | - | - | - |
| Total current assets | $741.36M | $529.71M | $398.41M |
| Property, plant & equipment | $5.69M | $1.96M | $377.00K |
| Goodwill | - | - | - |
| Total assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $937.13M |
| $753.95M |
| $401.40M |
| Accounts payable | $1.22M | $1.07M | $2.14M |
| Total current liabilities | $27.91M | $28.56M | $20.56M |
| Long-term debt | - | - | - |
| Total liabilities | $33.25M | $37.16M | $21.49M |
| Retained earnings | -$561.76M | -$305.92M | -$123.77M |
| Total equity | - | - | - |